- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01130792
Probiotics for Infectious Diarrhea in Children in South India
The overall goal of this study is to investigate whether the modulatory effects of probiotics, which are used as food supplements (Lactobacillus GG marketed as Culturelle or yoghurt) in the gastrointestinal tract promote restoration of intestinal function and enhance the specific immune response in children with cryptosporidial or rotaviral infections in South India. Rotavirus and Cryptosporidium spp. are the most important viral and parasitic causes of gastroenteritis in children in south India. Both infections can lead to severe dehydrating gastroenteritis in young children and have no specific treatment. Repeated episodes of diarrhea can result in long term deleterious effects on nutritional status, possibly due to intestinal damage. Most episodes of infectious gastroenteritis resolve without specific therapy, the mainstay of treatment being rehydration. However, oral rehydration remains under-utilized, in part due to the lack of effect on frequency of bowel movements and duration of illness. Due to the interest in simple, safe and effective measures to ameliorate the long-term effects of diarrheal illness, there is a growing appreciation for the potential of certain microorganisms to offer direct benefits to the health of a host. Probiotics are known to beneficially modulate several host functions, the most important of which are immune responses and intestinal barrier integrity. The investigators propose to build on the investigators previous collaborative efforts to conduct pilot studies to provide a mechanistic understanding of the effect of probiotic supplementation in children with rotaviral and cryptosporidial diarrhea.
Based on the established efficacy of LGG for the treatment of a variety of diarrheal diseases and the documented modulation of immune responses and strengthening of intestinal epithelial barrier function by probiotics, the investigators propose to conduct a Phase I/II double-blind randomized placebo controlled clinical trial to assess the preliminary efficacy and safety of LGG vs. placebo in the resolution of symptoms and restoration of intestinal function in children with either rotaviral or cryptosporidial diarrhea and no other detected enteric infection. Promising results in this Phase I/II study will provide preliminary data to power a future randomized trial on these critical outcomes following rotaviral or cryptosporidial infection.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, India, 632004
- Christian medical college
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female children aged 6 months to 5 years
- Diagnosis of rotaviral or cryptosporidial gastroenteritis (Rotavirus or
- Cryptosporidium EIA positive and three or more watery stools within a 24-hour period)
- No other enteric pathogen isolated from the stool at the time of enrollment
- Able to take the contents of study capsules mixed into food or milk
- No need for antibiotics for current illness
- No use of LGG/other probiotics within 30 days (yogurt consumption is not an exclusion criterion)
- HIV negative
- No severe malnutrition (WAZ score < 3SD below the median)
- No evidence of active bowel leak, acute abdomen or colitis
- No history of allergy
- Parent/guardian willing to report on compliance and side effects during the study period
- Families willing to provide informed consent, participate in study and have study personnel visit their home.
Exclusion criteria
- Other enteric pathogens isolated from the stool at the time of enrollment
- Not willing or able to take the contents of study capsules mixed into food or milk
- Need for antibiotics for current illness
- HIV positive
- Severe malnutrition (WAZ score < 3SD below the median)
- Presence of active bowel leak, acute abdomen or colitis
- History of allergy
- Parent/guardian not willing to report on compliance and side effects during the study period
- Families not willing to provide informed consent, participate in study or have study personnel visit their home.
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lactobacillus GG
LGG once daily for 4 weeks
|
10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
|
PLACEBO_COMPARATOR: Inulin
|
Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
IgG To Rotavirus VP6 Or Cryptosporidial Gp15
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
lactulose:mannitol test
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gagandeep Kang, MD, PhD, Christian Medical College, Vellore, India
- Principal Investigator: Honorine D Ward, MD, Tufts Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCHPROBIO
- R03HD057736 (NIH)
- CTRI/2010/091/000339 (REGISTRY: Clinical Trials Registry of India)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infectious Gastroenteritis
-
BioFire Diagnostics, LLCNational Institute of Allergy and Infectious Diseases (NIAID)CompletedInfectious GastroenteritisUnited States
-
Giulio DiDiodatoBiomerieux incCompletedInfectious GastroenteritisCanada
-
Cosmo Technologies LtdCompletedInfectious Diarrhoea
-
Luminex CorporationCompletedGastroenteritis | Infectious ColitisUnited States
-
International Centre for Diarrhoeal Disease Research...Karolinska Institutet; Georgetown University; University Hospital, Basel, SwitzerlandCompleted
-
Andrew MeltzerBioFire Diagnostics, LLCTerminatedInfectious DiarrheaUnited States
-
Assistance Publique - Hôpitaux de ParisBiofireCompletedAcute Diarrhea | Acute Colitis of Presumed Infectious OriginFrance
-
Johann Wolfgang Goethe University HospitalCompleted
-
Eveliqure Biotechnologies GmbHCompletedGastrointestinal Disease | Reactive Arthritis | Diarrheal Disease, InfectiousHungary
-
National Cheng-Kung University HospitalNot yet recruiting
Clinical Trials on Lactobacillus GG
-
National Institute of Pediatrics, MexicoNekutli S.A. de C.V.Completed
-
Duke UniversityCompletedMicrobiomeUnited States
-
Tufts Medical CenterTerminatedVancomycin Resistant Enterococcal ColonizationUnited States
-
Groningen Research Institute for Asthma and COPDNumico Research Wageningen, the NetherlandsCompletedAtopic Dermatitis | Atopic Eczema | Infantile EczemaNetherlands
-
Federico II UniversityUnknownCow's Milk AllergyItaly
-
Michael E. DeBakey VA Medical CenterBaylor College of MedicineWithdrawnEnterocolitis | Pseudomembranous Colitis | Antibiotic-associated ColitisUnited States
-
Pablo Román LópezCompleted
-
Shriners Hospitals for ChildrenTerminated
-
Virginia Commonwealth UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedMinimal Hepatic EncephalopathyUnited States
-
Medical University of WarsawUnknownRespiratory Tract Infections | Gastroesophageal Reflux Disease | Gastrointestinal InfectionsPoland